Currently Viewing:
Newsroom
Currently Reading
Sanofi Pasteur Announces It Will Discontinue Its Bladder Cancer Vaccine
November 18, 2016 – AJMC Staff
ICU Admission Reduces Survival, Augments Costs Among Patients With AML
November 17, 2016 – Surabhi Dangi-Garimella, PhD
Addressing the Psychosocial Needs in Older Breast Cancer Patients
November 17, 2016 – Surabhi Dangi-Garimella, PhD
First-in-Human Trial of CRISPR-Cas9 Begins in Lung Cancer Patients
November 16, 2016 – Surabhi Dangi-Garimella, PhD
BLA for Bevacizumab Biosimilar Filed Based on Phase 3 NSCLC Data
November 15, 2016 – Surabhi Dangi-Garimella, PhD
Combining IORT With Chemotherapy Improves Survival in Pancreatic Cancer
November 15, 2016 – Surabhi Dangi-Garimella, PhD
Prospective Trial Confirms Important Role of Vitamin D in Breast Cancer
November 14, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Trump Hints at Keeping Some Popular ACA Components
November 14, 2016 – AJMC Staff
Genetic Factors Can Help Tailor Surveillance Programs for Melanoma
November 12, 2016 – Surabhi Dangi-Garimella, PhD

Sanofi Pasteur Announces It Will Discontinue Its Bladder Cancer Vaccine

AJMC Staff
Sanofi Pasteur has announced that it has decided to discontinue production of the BCG vaccine, which is indicated for the treatment and prophylaxis of carcinoma in situ of the urinary bladder.
The hints were there when news trickled of a shortage of the BCG (bacille Calmette-Guerin) live intravesical (TheraCys Intravesical Injection) in September this year. Now, Sanofi Pasteur, the manufacturer of this vaccine—which is indicated for the treatment and prophylaxis of carcinoma in situ of the urinary bladder—has announced that it has decided to discontinue its production.

The news of a drug shortage of the vaccine was announced by the American Society of Health-System Pharmacists a couple of months back. In a letter announcing the decision, Sanofi says that the company did try to restore production to maintain long-term availability of the product, but the efforts fell short. The letter states that production at the drug manufacturing facility in Canada will halt by mid-2017. Anticipating this issue, Sanofi initiated a formal global process to find another company to take up manufacturing and commercialization of BCG, without success.

A problem that the company faced back in 2011 was the presence of mold infections at the manufacturing site, which was called out by the FDA. Merck, the other manufacturer of the vaccine, tried to fill in, but could not keep up with the demand. The next year will bring challenges for both providers and patients diagnosed with bladder cancer.

                                                           

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up